Topic: autoimmune disease
The deal sees Sygnature take a stake in Pathios in part payment for its involvement in the Oxford-based biotech’s hit-to-lead program.
IFM Therapeutics is unveiling its second subsidiary, IFM Due, which will target the cGAS/STING pathway to treat inflammatory and autoimmune disease.
The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials.
A University of Chicago teams has shown that a derivative of hypertension drug Wytensin can protect myelin in animal models of multiple sclerosis.
Provention Bio is developing a multivalent coxsackievirus vaccine for Type 1 diabetes and is on track to start clinical trials.
Researchers at the University of Toronto and UCSF point to the gut as the source of immune cells that mitigate brain inflammation in MS.
Chugai has the phase 3 data it needs to file IL-6-targeting antibody satralizumab for approval in neuromyelitis optica spectrum disorder next year.
A phase 2 win for its lead drug in myasthenia gravis has Ra Pharma pressing the button on a $115 million public funding round.
Principia has started a phase 3 program for its BTK inhibitor in the autoimmune disease pemphigus after hitting the target in a midstage trial.
Capitalizing on a process the body uses to eliminate overly aggressive T cells could be a new way to treat autoimmune diseases.